P4 - Plenary Session IV: Remuneration of pharmaceutical services in primary health care

Meeting room: Avicenna

Rapporteur: Rashida Umar, Medipol University Faculty of Pharmacy

Chairs

Paul Sinclair, Chair, FIP Board of Pharmaceutical Practice, Australia and Michał Byliniak, President, Pharmaceutical Group of European Union, Belgium

Introduction

Supported by the Pharmaceutical Group of the European Union (PGEU)

Pharmacists can play an important role in primary health care, namely in disease prevention through the modification of risk factors. This requires pharmacists’ time and expertise, and it clearly generates savings for health care payers and patients. Remunerating such qualified services seems to be a sound investment by health systems, and yet it is a major challenge in many countries. How can we address this paradigm shift in funding primary health care?

Programme

  1. 16:00 – 16:05 Introduction by chairs
  2. 16:05 – 16:25 Remuneration models reflecting the contribution of pharmacists in primary health care
    Dominique Jordan, President, FIP, Switzerland
  3. 16:25 – 16:45 Pharmaceutical services supporting the sustainability of health systems
    Sónia Queirós, Head of International Affairs, National Pharmacy Association, Portugal
  4. 16:45 – 16:55 Q&A
  5. 16:55 – 17:30 Panel discussion moderated by chairs
    Panelists:Dominique Jordan, President, FIP, Switzerland

    Sónia Queirós, Head of International Affairs, National Pharmacy Association, Portugal

    Lieven Zwaenepoel, Vice President, Association of Pharmacists Belgium, Belgium

    Per Kristian Faksvåg, Director of Professional Affairs, Norwegian Pharmacy Association, Norway

    Jan de Belie, Professional Affairs Advisor, Pharmaceutical Group of European Union, Belgium

Learning Objectives

At the end of this session, participants will be able to:

  1. Become familiar with alternative funding models for primary health care in general, and for pharmacists’ services in particular.
  2. Understand how to build the case when advocating for remuneration for pharmacists’ services.
  3. Understanding the barriers and challenges for service remuneration.
  4. Understanding the importance of generating and using evidence to support a change in remuneration models.